Claims for Patent: 8,617,569

Summary for Patent: 8,617,569

Title:	Treatment of migraine headache with diffusion of toxin in non-muscle related foraminal sites
Abstract:	A method for treating a patient with migraine headache includes administering to the patient a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form. The administration includes extramuscular injection of the neurotoxin to emerging nerve points including foraminal sites for enabling neurotoxin access to concentrated nerve bundles at exit points of the foramina.
Inventor(s):	Binder; William J. (Beverly Hills, CA)
Assignee:
Application Number:	13/478,602
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,617,569
Patent Claims:	1. A method for treating a human patient with migraine headache, said method comprising: administering to the patient a therapeutically effective amount of a neurotoxin which is a Botulinum toxin or a tetanus toxin in a pharmaceutically safe form; and the administration comprising extramuscular injection of the neurotoxin to unmyelinated C fibers at emerging nerve exit points, wherein said nerve exit points are one or more of the Great auricular, Auriculotemporal, Supraorbital, Supratrochlear, Infratrochlear, Infraorbital or Mental nerve exit points. 2. The method of claim 1, wherein the neurotoxin is Botulinum toxin. 3. The method of claim 2, wherein the Botulinum toxin is Botulinum toxin A. 4. The method of claim 3, wherein the Botulinum toxin A is onabotulinumtoxinA. 5. The method of claim 2, wherein the Botulinum toxin is Botulinum toxin B. 6. The method according to claim 2, wherein the Botulinum toxin is administered in a concentrated form of about 1 cc of normal saline to 100 units of Botulinum toxin thereby causing less rapid tissue expansion upon injection resulting in less pain. 7. The method according to claim 1, wherein the neurotoxin comprises an Endotoxin. 8. The method of claim 7, wherein the Endotoxin is an endopeptidase derived from Botulinum toxin. 9. The method of treating a human patient with migraine headache, said method comprising administering to the patient a therapeutically effective amount of Botulinum toxin A in a pharmaceutically safe form; the administration comprising extramuscular injection of the Botulinum toxin A in a concentrated form of about 1 cc per 100 units of botulinum toxinA to one or more of the Great auricular Auriculotemporal, Supraorbital, Supratrochlear, Infratrochlear, Infraorbital, and Mental nerve exit points.

Details for Patent 8,617,569

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Allergan, Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	12/09/1991		2032-03-12
Allergan, Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	12/09/1991		2032-03-12